Cite
Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway.
MLA
Dai, Chunyan, et al. “Physapubescin B Enhances the Sensitivity of Gastric Cancer Cells to Trametinib by Inhibiting the STAT3 Signaling Pathway.” Toxicology & Applied Pharmacology, vol. 408, Dec. 2020, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.taap.2020.115273.
APA
Dai, C., Shen, L., Jin, W., Lv, B., Liu, P., Wang, X., Yin, Y., Fu, Y., Liang, L., Ma, Z., Zhang, X., Wang, Y., Xu, D., & Chen, Z. (2020). Physapubescin B enhances the sensitivity of gastric cancer cells to trametinib by inhibiting the STAT3 signaling pathway. Toxicology & Applied Pharmacology, 408, N.PAG. https://doi.org/10.1016/j.taap.2020.115273
Chicago
Dai, Chunyan, Li Shen, Weiyang Jin, Bing Lv, Pei Liu, Xi Wang, Yifei Yin, et al. 2020. “Physapubescin B Enhances the Sensitivity of Gastric Cancer Cells to Trametinib by Inhibiting the STAT3 Signaling Pathway.” Toxicology & Applied Pharmacology 408 (December): N.PAG. doi:10.1016/j.taap.2020.115273.